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A B S T R A C T
Polychlorinated biphenyls (PCBs) are metabolized by cytochrome P450 2B enzymes (CYP2B) and nicotine
is reported to alter CYP2B activity in the brain and liver. To test the hypothesis that nicotine inﬂuences
PCB disposition, 2,20,3,50,6-pentachlorobiphenyl (PCB 95) and its metabolites were quantiﬁed in tissues
of adult male Wistar rats exposed to PCB 95 (6 mg/kg/d, p.o.) in the absence or presence of nicotine
(1.0 mg/kg/d of the tartrate salt, s.c.) for 7 consecutive days. PCB 95 was enantioselectively metabolized to
hydroxylated (OH-) PCB metabolites, resulting in a pronounced enrichment of E1-PCB 95 in all tissues
investigated. OH-PCBs were detected in blood and liver tissue, but were below the detection limit in
adipose, brain and muscle tissues. Co-exposure to nicotine did not change PCB 95 disposition.
CYP2B1 mRNA and CYP2B protein were not detected in brain tissues but were detected in liver. Co-
exposure to nicotine and PCB 95 increased hepatic CYP2B1 mRNA but did not change CYP2B protein levels
relative to vehicle control animals. However, hepatic CYP2B protein in animals co-exposed to PCB 95 and
nicotine were reduced compared to animals that received only nicotine. Quantiﬁcation of CYP2B3,
CYP3A2 and CYP1A2 mRNA identiﬁed signiﬁcant effects of nicotine and PCB 95 co-exposure on hepatic
CYP3A2 and hippocampal CYP1A2 transcripts. Our ﬁndings suggest that nicotine co-exposure does not
signiﬁcantly inﬂuence PCB 95 disposition in the rat. However, these studies suggest a novel inﬂuence of
PCB 95 and nicotine co-exposure on hepatic cytochrome P450 (P450) expression that may warrant
further attention due to the increasing use of e-cigarettes and related products.
ã 2015 Elsevier Ireland Ltd. All rights reserved.
Contents lists available at ScienceDirect
Toxicology
journa l homepage : www.e l sev ier .com/ loca te / toxicol1. Introduction
Nicotine is a highly addictive component of cigarette smoke,
e-cigarettes and other tobacco products (Yamin et al., 2010; Noel
et al., 2011; Regan et al., 2013) that rapidly crosses the blood–brain
barrier to upregulate cytochrome P450 enzymes (Anandatheer-
thavarada et al., 1993a; Miksys et al., 2000). CYP2B6 is upregulated
in the brain of human smokers (Miksys et al., 2003), and nicotineAbbreviations: Ct, fractional ampliﬁcation (cycle number at which ﬂuorescence
exceeds a user-deﬁned threshold); d, day; b.w., body weight; DE, diatomaceous
earth; EF, enantiomeric fraction; qPCR, quantitative (real-time) polymerase chain
reaction; PCBs, polychlorinated biphenyls; P450, cytochrome P450.
* Corresponding author at: Department of Molecular Biosciences, UC Davis
School of Veterinary Medicine, 1089 Veterinary Medicine Drive, Davis, CA 95616,
USA. Fax: +1 530 752 7690.
E-mail address: pjlein@ucdavis.edu (P.J. Lein).
1 These authors contributed equally to this manuscript.
http://dx.doi.org/10.1016/j.tox.2015.10.002
0300-483X/ã 2015 Elsevier Ireland Ltd. All rights reserved.has been reported to increase CYP2B expression in the brain of rats
and non-human primates while either reducing or not changing
hepatic CYP2B expression (Miksys et al., 2000; Lee et al., 2008).
These effects of nicotine on CY2B expression in the brain have been
linked to altered in vivo pharmacokinetics and pharmacodynamics
of the neuroactive compound propofol (Khokhar and Tyndale,
2011).
Human CYP2B6 also metabolizes neurotoxic environmental
contaminants including polychlorinated biphenyls (PCBs)
(Ariyoshi et al., 1995; Warner et al., 2008), polybrominated
diphenyl ethers (PBDEs) (Feo et al., 2012) and organophosphorus
pesticides (Crane et al., 2012). CYP2B-mediated metabolism alters
the neurotoxic potential of PCBs and PBDEs (Kim et al., 2011;
Niknam et al., 2013), and is important in both bioactivation and
detoxiﬁcation of organophosphorus pesticides (Foxenberg et al.,
2011). Collectively, these studies suggest that nicotine exposure
may inﬂuence neurotoxicity by modulating CYP2B activity in the
60 M. Stamou et al. / Toxicology 338 (2015) 59–68brain or liver, thereby altering toxicant levels local to cellular
targets.
Here we test the hypothesis that repeated nicotine co-exposure
alters the disposition of PCB 95 and its metabolites. PCB 95 was
chosen for these studies because it is linked to neurotoxic
outcomes in humans and rats (Pessah et al., 2010) and it is
metabolized by CYP2B1 in rats (Warner et al., 2008; Lu et al., 2013).
Furthermore, PCB 95 is a chiral molecule that exists as two
non-superimposable mirror images called enantiomers, and the
CYP2B-mediated metabolism of PCB 95 is enantioselective (Lu
et al., 2013; Kania-Korwel and Lehmler, 2015). Thus, monitoring
the enantiomeric signatures of PCB 95 and its metabolites is
expected to provide a sensitive readout for investigating changes
in P450 enzyme activities in the brain.
We detected PCB 95 in all tissues investigated, including the
cortex and cerebellum, and observed considerable enantiomeric
enrichment of the ﬁrst eluting PCB 95 atropisomer; however, co-
exposure to nicotine did not alter PCB 95 disposition in the brain or
liver. CYP2B1 mRNA and CYP2B protein were not detected in rat
brain, and nicotine treatment had no signiﬁcant effect on levels of
CYP2B1, CYP2B3, CYP3A2 and CYP1A2 mRNA or CYP2B protein in
the brain. In contrast, we observed a novel inﬂuence of PCB and
nicotine co-exposure on the expression of hepatic CYP2B1 and
CYP3A2 mRNA.
2. Material and methods
2.1. Chemicals
2,20,3,50,6-Pentachlorobiphenyl (PCB 95; 99.7% purity),
2,3,40,5,6-pentachlorobiphenyl (PCB 117; 99% purity),
2,20,3,4,40,5,6,60-octachlorobiphenyl (PCB 204; 99.9% purity) and
20,3,30,4,5,50-hexachlorobiphenyl-40-ol (4-159, >99.9% purity) were
purchased from AccuStandard (New Haven, CT, USA). 3-Methoxy-
2,20,4,50,6-pentachlorobiphenyl (3-103), 2,20,3,50,6-pentachlorobi-
phenyl-4-ol (4-95), 2,20,3,50,6-pentachlorobiphenyl-40-ol (40-95),
2,20,3,50,6-pentachlorobiphenyl-5-ol (5-95) and 4,5-dimethoxy-
2,20,3,50,6-pentachlorobiphenyl (4,5-95) were synthesized at >95%
purity as described previously (Kania-Korwel et al., 2008; Joshi
et al., 2011). The respective chemical structures and abbreviations
are shown in Fig. 1. ()-Nicotine hydrogen tartrate salt (98% purity;
CAS number 65-31-6) was purchased from Sigma–Aldrich
(St. Louis, MO, USA). 1H and 13C NMR spectra conﬁrmed that the
nicotine hydrogen tartrate salt was highly pure (see Supplemental
data, Figs. S1 and S2).Fig. 1. Simpliﬁed scheme of PCB 95 biotransformation showing metabolites unambig
tentatively identiﬁed as 30-95 (X1) and 30 ,40-95 (X2).2.2. Animals and treatments
Animals were maintained in facilities fully accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care International, and all studies were carried out in
accordance with the Guide for the Care and Use of Laboratory
Animals as adopted and promulgated by the U.S. National
Institutes of Health, and with regard for alleviation of pain
and suffering under protocols approved by the UC Davis
Institutional Animal Care and Use Committee. Adult male Wistar
rats (50–55 days old; 209–270 g; Charles River Laboratories,
Hollister, CA) were housed individually in standard plastic cages
under controlled environmental conditions (22  2 C, 40–50%
humidity) with a normal 12 h light/dark cycle. Food and water
were provided ad libitum.
Animals were allowed to acclimate for 48 h after delivery to the
UC Davis vivarium and then randomly divided into eight
experimental groups with four animals per experimental group
(Fig. 2): (i) nicotine in sterile saline (1 mg/kg/d, s.c.) for 7 d plus PCB
95 (6 mg/kg/d, p.o. in peanut butter) for days 1–6; (ii) an equal
volume of vehicle (sterile saline, 0.3 ml/d, s.c.) for 7 d plus PCB 95
(6 mg/kg/d, p.o. in peanut butter) for days 1–6; (iii) nicotine in
sterile saline (1 mg/kg/d, s.c.) for 7 d; or (iv) vehicle (sterile saline,
0.3 ml/d, s.c.) for 7 d. To assess transient effects of nicotine on
CYP2B1 expression in the brain, a subset of rats were injected daily
with: (v) nicotine (1 mg/kg/d, s.c.) for 1 d or (vi) 3 d; or (vii) an equal
volume of vehicle (sterile saline, 0.3 ml/d, s.c.) for 1 d or (viii) 3 d
(Fig. 2).
The dose and route of administration of nicotine was based on
previous studies demonstrating that daily s.c. injection with
0.3 mg/kg nicotine free base for 7 consecutive days signiﬁcantly
increased CYP2B1 mRNA levels in the cortex of adult male Wistar
rats compared to vehicle controls (Miksys et al., 2000). The tartrate
salt of nicotine was administered at 1 mg/kg b.w. (2 mmol/kg b.w.),
which translates to a dose of 325 mg/kg of nicotine as the free base
(Matta et al., 2007). This dose results in blood nicotine levels in the
rat comparable to levels in human smokers following 10 cigarettes
(Le Houezec et al.,1993). The PCB 95 dose (6 mg/kg/d, which equals
18.4 mmol/kg/d) was based on our previous studies of PCB
95 enantiomeric disposition in the mouse brain (Kania-Korwel
et al., 2012). The route of administration of PCB 95 was previously
described (Kania-Korwel et al., 2012), and rats consumed the
peanut butter mix within minutes.
Animals were euthanized by carbon dioxide inhalation 4 h
after the last nicotine injection (approximately 28 h after the lastuously identiﬁed with authentic standards, as well as two unknown metabolites
Fig. 2. Schematic illustrating the experimental design. Animals were randomly divided into eight experimental groups (n = 4 animals per experimental group) and dosed with
(i) nicotine in saline for 7 d plus PCB 95 for days 1–6; (ii) saline for 7 d plus PCB 95 for days 1–6; (iii) nicotine in saline for 7 d; (iv) saline for 7 d; (v) nicotine in saline for 3 d; (vi)
nicotine in saline for 1 d; (vii) saline for 3 d; or (viii) saline for 1 d. Nicotine was administered as the tartrate salt at 1 mg/kg/d, s.c.; PCB was administered at 6 mg/kg/d, p.o.
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liver, and brains were immediately collected and brains were
microdissected on ice to isolate the cortex, hippocampus and
cerebellum. All tissues used for analysis of tissue PCB levels were
wrapped in aluminum foil, snap-frozen in liquid nitrogen and
stored at 80 C until analyzed. Tissues used for qPCR and western
blot analyses were stored overnight in RNAlater (Life Technolo-
gies). The following morning, samples were removed from
RNAlater and stored at 80 C until further processed.
2.3. PCB and OH-PCB tissue extraction, clean-up and analysis
Tissue samples were extracted as described previously (Kania-
Korwel et al., 2012). Brieﬂy, cortex (0.15–0.31 g), cerebellum
(0.098–0.190 g), liver (0.26–0.46 g), blood (0.65–1.28 g), muscle
(0.19–0.46 g), and adipose (0.040–0.080 g) samples were homoge-
nized with pre-extracted diatomaceous earth (DE) (2 g) and placed
in 33 ml size extraction cells over pre-extracted Florisil1 (12 g).
Blood aliquots were evenly distributed on top of extraction cells
containing pre-extracted Florisil and pre-extracted DE. Each batch
of samples was accompanied by a method blank (DE and Florisil
only, no tissue) and matrix blanks (tissue from non-PCB exposed
animal). Surrogate recovery standards, PCB 117 (50 ng) and 4–159
(68.5 ng), were added to each cell. The samples were extracted
using a pressurized solvent extraction system (ASE 200, Dionex1,
Sunnyvale, CA, USA) with hexane: dichloromethane: methanol
(48:43:9, v/v) as solvent at 100 C, 1500 psi (10 MPa) with preheat
equilibration of 6 min, 35% cell ﬂush volume, and 1 static cycle of
5 min. The extracts were concentrated, derivatized with diazo-
methane and subjected to a sulfur cleanup step (Kania-Korwel
et al., 2007, 2008).
The ﬁnal organic extract was analyzed using an Agilent 7870A
gas chromatograph equipped with a 63Ni micro-electron capture
detector (GC-ECD) and a SPB 1 column (60 m, 0.25 mm inner
diameter, 0.25 mm ﬁlm thickness; Supelco, St. Louis, MO, USA)
(Kania-Korwel et al., 2012). The injector was operated in splitless
mode at a temperature of 280 C, with the detector temperature at
300 C. The temperature program started at 50 C for 1 min, then
30 C/min to 200 C, 1 C/min to 250 C, and 10 C/min to 280 C.
Concentrations of PCB 95 and its hydroxylated metabolites (as
methylated derivatives) were determined using PCB 204 as theinternal standard. The overall recoveries of PCB 117 and 4–159 were
104  39% and 65  20%, respectively. Limits of detection for the
quantiﬁcation of PCB 95 and its metabolites in tissues are
summarized in Table S1, Supplemental data. The presence of
several hydroxylated PCB 95 metabolites identiﬁed in the GC-ECD
analysis (Fig. S3) was conﬁrmed by gas chromatography–mass
spectrometry (GC–MS) analysis, as shown in Fig. S4.
Enantioselective analyses of PCB 95 were performed on an
Agilent 7890 gas chromatograph equipped with a 63Ni m-ECD and a
Chirasil-Dex column (2,3,6-tri-O-methyl-b-cyclodextrin; 30 m,
250 mm inner diameter, 0.12 mm ﬁlm thickness; Agilent, Santa
Clara, CA, USA) (Kania-Korwel et al., 2012). The following
temperature program was used: initial temperature was held at
90 C for 1 min, then increased at 30 C/min to 160 C, hold for
20 min, 1 C/min to 170 C, hold for 7 min, 1 C/min to 190 C, hold
for 20 min, 10 C/min to 200 C, hold for 20 min. Since the elution
order of the PCB95 atropisomers is unknown, the enantiomeric
fractions (EF) were calculated as EF = A1/(A1 + A2) where A1 and
A2 are the peak area of the ﬁrst and the second eluting PCB 95
atropisomers (Kania-Korwel et al., 2012). The EF of racemic PCB
95 was 0.498  0.007 (n = 7), with a resolution of the PCB
95 atropisomers of 0.8  0.1 on the Chirasil-Dex column. Enantio-
selective analyses of PCB 95 in cerebellum and of OH-PCBs in all
tissues investigated were not possible due to their low levels in the
tissue extracts.
2.4. Preparation of microsomes from liver and cortex
Microsomes were prepared as previously described with minor
modiﬁcations (Khokhar et al., 2010). Brieﬂy, frozen samples of liver
and cortex were thawed and homogenized in buffer containing
0.1 M Tris (pH 7.4), 0.32 M sucrose, 1% EDTA and 1% dithiothreitol,
using a Polytron PT 1200E tissue homogenizer (Kinematica,
Bohemia, NY). The homogenate was centrifuged twice at
9000  g for 5 min at 4 C. The supernatant was then ultra-
centrifuged at 110,000  g for 90 min at 4 C. The resulting pellet
was suspended in 0.1 M Tris buffer (pH 7.4) containing 1.15%
potassium chloride, 20% glycerol, 1% EDTA and 1% dithiothreitol
and stored at 80 C until further use. Microsomal protein
concentrations were determined using the Pierce BCA Protein
Assay Kit (Thermo Scientiﬁc, Waltham, MA).
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Total protein from liver and cortical microsomes (30 mg
microsomal protein per lane) was separated by SDS PAGE using
Bolt Bis–Tris Plus Gels (Life Technologies, Carlsbad, CA),
transferred onto PVDF membranes (iBlot Transfer Stacks, Life
Technologies) using the iBlot 2 dry transfer system (Life
Technologies) and immunoblotted using the iBind Western
System (Life Technologies). Blots were probed with 2 different
CYP2B antibodies: (i) a commercially available mouse monoclonal
antibody that recognizes CYP2B1/2 (10R-C154A, Batch number
91895 DM, Fitzgerald Industries International, Acton, MA) and
was previously used in immunoprecipitation experiments to
assess CYP2B1 activity in adult male Wistar rat brains (Khokhar
et al., 2010; Khokhar and Tyndale, 2011); and (ii) a rabbit
polyclonal anti-CYP2B IgG antibody (generously provided by
Stelvio Bandiera, University of British Columbia) previously
demonstrated to react with rat liver CYP2B1, CYP2B2 and a third
non-inducible enzyme of the CYP2B family but not with any other
rat P450 proteins (Panesar et al., 1996). All samples were also
probed with a rabbit monoclonal anti-GAPDH (2118, Lot number
8, Signaling Systems, Danvers, MA) (Siemens et al., 2011) as a
loading control. The CYP2B1/2 Ab from Fitzgerald Industries
was used at 1:20 dilution; the CYP2B Ab from Dr. Bandiera, at
20 mg/ml (1:130 dilution); and the anti-GAPDH at 1:200 dilution.
Antibody-antigen complexes were detected using IRDye800-
conjugated goat anti-rabbit IgG (611-132-122, Lot number 23641,
Rockland, Gilbertsville, PA, diluted 1:2000), to detect the rabbit
anti-GAPDH and the rabbit anti-CYP2B1, and IRDye700DX-
conjugated goat anti-mouse IgG (610-130-121, Lot number
13508, Rockland, diluted 1:2000) to detect the mouse anti-
CYP2B1. Membranes were scanned using the Odyssey Infrared
Imaging System (LI-COR) to identify immunopositive bands.
Proteins were identiﬁed based on size (approximately 56 kDa for
CYP2B and 37 kDa for GAPDH). Each sample was analyzed in three
independent experiments, randomizing the order of sample
loading each time. Samples containing only loading buffer were
used as negative controls. Microsomal protein (0.13 mg/lane) from
the livers of phenobarbital-induced adult male Sprague Dawley
rats (Wu et al., 2011); and cDNA-expressed CYP2B1 (Supersomes;
456510, Corning, Woburn, MA; 3 mg/lane) were used as positive
controls. Densitometric analysis of immunoblots was performed
using Image Studio Lite 4.0 software (Licor Biotechnology,
Lincoln, NE). Densitometric data for CYP2B immunopositive
bands were normalized to GAPDH immunopositive bands from
the same sample.
2.6. Quantitative polymerase chain reaction analyses
Total RNA extraction, cDNA synthesis and quantitative poly-
merase chain reaction (qPCR) were performed at the Real-Time
PCR Research and Diagnostics Core Facility at UC Davis. Analysis of
the results and quantiﬁcation of gene transcript levels was
performed using SDS 2.4.1 (Applied Biosystems, Carlsbad, CA)
and REST 2009 software (Qiagen, Valencia, CA). Transcripts were
quantiﬁed for the target genes CYP2B1, CYP2B3, CYP3A2 and
CYP1A2; transcripts were also quantiﬁed for three reference genes:
phosphoglycerate kinase 1 (Pgk1), peptidylpropyl isomerase A
(Ppia) and hypoxanthine-guanine phosphoribosyl transferase
(Hprt). The primer and probe sequences for each of these
transcripts are listed in Table S2 of Supplemental data. The
speciﬁcity of our primer set for CYP2B1 (Stamou et al., 2014) has
been conﬁrmed using the BLASTN function on the NCBI website
(http://www.ncbi.nlm.nih.gov/tools/primer-blast), and is not
predicted to amplify CYP2B2 or any other P450 of the Rattus
Norvegicus species.The expression of target genes were normalized either against
Pgk1 expression alone or against the geometric mean of the
expression of Pgk1, Ppia and Hprt within the same sample, and the
relative expression ratios between treated and vehicle control
animals were calculated by the Pfafﬂ method (Pfafﬂ, 2001), using
the REST 2009 software as previously described (Stamou et al.,
2014). A more detailed description of these methods is provided in
the Supplemental data.
2.7. Statistical analysis
Treatment-related differences in the levels of the PCB 95 parent
compound and hydroxylated metabolites were analyzed using
Student’s t-test. EF values were compared between the experi-
mental groups and against the racemic standard using Student’s
t-test. Student’s t-test was performed with adjustment for multiple
comparisons, with p < 0.05 considered signiﬁcant. Statistical
analysis of the qPCR data was performed using the built-in
randomization techniques of REST 2009 software (Stamou et al.,
2014) as described in the Supplemental data. Densitometric data
were analyzed by one-way ANOVA with Tukey’s post hoc test using
Graphpad Prism (v. 5.01, La Jolla, CA).
3. Results
3.1. Effect of nicotine co-exposure on the disposition of PCB 95
Adult male Wistar rats were co-exposed to nicotine and PCB 95
(experimental groups (i) and (ii); Fig. 2), and levels of the PCB 95
parent compound (Fig. 3) and its hydroxylated metabolites (Fig. 4)
were quantiﬁed in cortex, cerebellum, adipose, blood, liver and
muscle. The small size of the hippocampus precluded measure-
ments of PCB 95 or its metabolites in this brain region. The parent
PCB was readily detected in the cortex and cerebellum (Fig. 3A).
Co-exposure to nicotine for 7 d had no effect on the levels of the
parent compound in any tissue investigated (Fig. 3A). In both
experimental groups, the levels of PCB 95 were signiﬁcantly higher
in adipose than in the other tissues investigated and decreased in
the rank order adipose > liver > cerebellumcortexskeletal mus-
cle > blood (Fig. 3A and Table S3 of the Supplemental data). These
observations are consistent with previous reports indicating that
the highest levels of chiral PCB congeners, including PCB 95, are
found in the adipose (Birnbaum, 1983; Kania-Korwel et al., 2012),
which is the major storage site for lipophilic compounds.
No hydroxylated PCB 95 metabolites were detected in the
cortex, cerebellum or skeletal muscle of animals exposed to PCB
95 in the absence or presence of nicotine. In adipose tissue, only
5–95 was detected as a minor metabolite in both experimental
groups (data not shown). However, consistent with previous
ﬁndings in mice (Kania-Korwel et al., 2012), several OH-PCB
metabolites were detected in the blood (Fig. 4A) and liver (Fig. 4B)
of both experimental groups, including 3–103 (1,2-shift product),
4–95, 40–95, 5–95 and 4,5–95. In both groups, 4,5–95 was a major
metabolite in blood (Fig. 4A), while 40–95, 5–95 and 4,5–95 were
the predominant metabolites in the liver (Fig. 4B). In addition to
the OH-PCB metabolites shown in Fig. 4, two unknown metabolites
were detected in the liver in both experimental groups and in the
pooled blood sample from both experimental groups (Figs. S3 and
S4 of the Supplemental data). Based on their molecular weight and
retention time, these metabolites are likely 30–95 and 30,40–95;
however, neither metabolite could be unambiguously identiﬁed
because authentic standards were not available. Importantly, no
statistically signiﬁcant differences were observed in the levels
of any of the identiﬁed metabolites in blood or liver of animals
co-exposed to nicotine and PCB 95 versus animals exposed to PCB
95 alone (Fig. 4A and B).
Fig. 3. Co-exposure to nicotine does not alter the levels and enantiomeric fractions
of PCB 95 in the male rat brain or peripheral tissues. (A) Levels of the parent
compound PCB 95 in the cortex and cerebellum of rats co-exposed to nicotine and
PCB 95 were not signiﬁcantly different than in rats exposed to vehicle (saline) and
PCB 95. Similarly, nicotine co-treatment had no effect on PCB 95 levels in liver,
blood, adipose or muscle (Student’s t-test; p < 0.05; n = 4 animals per experimental
group). Speciﬁc tissue concentrations are provided in Table S4 of the Supplemental
data. (B) Nicotine co-exposure did not signiﬁcantly modify PCB 95 atropisomer
distribution, expressed as the enantiomeric fraction (EF) of the ﬁrst-eluting
atropisomer of PCB 95 on a Chirasil-Dex column relative to the two isomers
combined (Student’s t-test; p < 0.05; n = 4 animals per experimental group, unless
otherwise noted). The ﬁrst-eluting atropisomer (E1-PCB 95) displayed a pro-
nounced enrichment in both experimental groups across all tissues investigated.
Because of the low PCB 95 levels in blood and muscle, extracts from all blood
samples (n = 8) and all muscle samples within each experimental group
(n = 4 animals per experimental group) were pooled to allow EF determination
in a single sample. Otherwise, all data represent the mean  standard deviation. The
dashed line corresponds to the EF of the racemic PCB 95 standard. All EF values were
signiﬁcantly different from the racemic standard (Student’s t-test; p < 0.05). ND not
detected. $p = 0.052. Bar with downward diagonals: EF of all blood samples (n = 8)
pooled into a single sample. Data are from experimental groups (i) and (ii) as
described in Section 2.2 and illustrated in Fig. 2.
M. Stamou et al. / Toxicology 338 (2015) 59–68 633.2. Effect of nicotine co-exposure on the enantioselective enrichment
of PCB 95
In mice, PCB 95 and its metabolites exhibit enantiomeric
enrichment in the brain that is either a result of enantioselective
hepatic metabolism by CYP2B1 enzymes (Kania-Korwel et al.,
2012; Lu et al., 2013) or may be mediated by localized metabolism
in the brain (Dutheil et al., 2010; Miksys and Tyndale, 2013).
Because changes in the enantiomeric enrichment of PCB 95 are
likely sensitive to altered CYP2B expression (Lehmler et al., 2010),
we evaluated the enantiomeric enrichment of PCB 95 and its
metabolites in the brain and peripheral tissues from both
experimental groups dosed with PCB 95 (Fig. 2). Enantioselective
analysis for the PCB 95 parent compound on a Chirasil-Dex column
revealed predominant enrichment of the ﬁrst eluting atropisomerof PCB 95 (E1-PCB 95; E1 and E2 denote the elution order of the
enantiomers in the enantioselective analysis), with EF values
ranging from 0.84 to 0.97 (Fig. 3B; Table S5). Enrichment of E1-PCB
95 was conﬁrmed by spiking samples with a low amount of PCB
95 racemic standard and reanalyzing the samples. In both
experimental groups, tissue EF values for PCB 95 followed the
rank order: blood (sample pooled across experimental groups) >
livermuscle (samples pooled within experimental groups) >
cortex > adipose. There were no signiﬁcant differences in the EF
values of PCB 95 between the nicotine + PCB 95 versus saline + PCB
95 treatment groups (e.g., experimental groups (i) and (ii)).
3.3. Effect of nicotine treatment on CYP2B protein levels in rat brain or
liver
To determine whether nicotine altered the expression of CYP2B
protein in the brain or liver at the dose investigated, western
blotting was used to quantify CYP2B proteins in microsomes
isolated from the cortex and liver of animals treated with saline,
nicotine, saline plus PCB 95, or nicotine plus PCB 95 (experimental
groups (i)–(iv), see Fig. 2). Proteins at the expected molecular
weight for CYP2B1/2 (56 kDa) were not detected in any cortex or
liver microsomes when blots were probed with a monoclonal
antibody obtained from the same source as one previously used to
quantify CYP2B1 protein in the adult male Wistar brain by
immunoprecipitation (Khokhar et al., 2010; Khokhar and Tyndale,
2011) (data not shown). This antibody also did not react with liver
microsomes from phenobarbital-induced rats or with recombinant
CYP2B1 (data not shown). Microsomal preparations were then
probed using a different antibody previously shown to selectively
recognize CYP2B1, CYP2B2 and an unidentiﬁed non phenobarbital-
inducible CYP2B enzyme (Panesar et al., 1996). This second
antibody recognized recombinant rat CYP2B1 and reacted robustly
with liver microsomes from phenobarbital-induced rats (Fig. 5).
This antibody also cross-reacted with proteins at 56 kDa in liver
but not cortical microsomes from all four experimental groups
(Fig. 5A–C). Densitometric analyses of CYP2B immunoreactive
bands indicated that neither nicotine nor PCB 95 alone changed
hepatic CYP2B levels relative to vehicle controls. However,
co-exposure to nicotine and PCB 95 signiﬁcantly decreased levels
of CYP2B protein in liver microsomes relative to nicotine exposure
alone (Fig. 5D).
3.4. Effect of co-exposure to nicotine and PCB 95 on CYP2B1 mRNA
expression
CYP2B1 transcripts were quantiﬁed using qPCR to further
investigate whether nicotine upregulates CYP2B1 in the brain or
liver using two different primer/probe sets: (i) a primer/probe set
previously designed and validated in our laboratory (Stamou et al.,
2014), which was conﬁrmed to be speciﬁc for CYP2B1 and
predicted to not amplify CYP2B2 or any other P450 of the R.
Norvegicus species (see Section 2.6); and (ii) a set consisting of a
primer pair previously used to show nicotine-induced CYP2B1
expression in the brain (Miksys et al., 2000), which when blasted
against the R. Norvegicus genome, identiﬁed CYP2B3 as a potential
non-intended target. The second primer set was combined with a
probe designed in-house (Table S2 of the Supplemental data).
CYP2B1 mRNA was not detected by either CYP2B1 primer/probe
set in the cortex, hippocampus or cerebellum of any experimental
group (Tables 1 and 2), suggesting that exposure to PCB 95 or
nicotine alone or in combination did not induce CYP2B1 mRNA
expression in the brain. In contrast, CYP2B1 mRNA was detected in
the liver of all animals across all experimental groups (Tables 1 and
2). Exposure to either nicotine or PCB 95 alone did not signiﬁcantly
change hepatic CYP2B1 transcript levels relative to vehicle controls
Fig. 4. Levels of OH-PCB 95 metabolites in (A) blood and (B) liver are not
signiﬁcantly altered by nicotine co-exposure in male Wistar rats. Data are from
experimental groups (i) and (ii) as described in Section 2.2 and illustrated in Fig. 2.
Data are presented as the mean  standard deviation (n = 4 animals per
experimental group). No statistically signiﬁcant differences between experimental
groups were identiﬁed using Student’s t-test at p < 0.05. Speciﬁc tissue levels of
OH-PCB 95 metabolites are reported in Table S4.
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cantly increased hepatic CYP2B1 mRNA levels (2.8-fold; p = 0.04;
n = 4 animals per experimental group) relative to vehicle controls,
but not relative to animals exposed to either nicotine or PCB 95
alone (Table 2).
3.5. Effect of co-exposure to nicotine and PCB 95 on transcript levels of
other P450 enzymes in rat brain and liver
To further characterize the effects of nicotine and PCB 95 on
P450 mRNA expression in the brain and liver, transcript levels of
additional P450 enzymes were quantiﬁed including: (i)
CYP3A2 and CYP1A2, both of which have previously been
implicated in the metabolism of persistent organic pollutants,
including PCBs (Hrycay and Bandiera, 2003); and (ii) CYP2B3,
which is highly homologous to CYP2B1. Both CYP2B1 and CYP2B3
are homologous (86% and 78%, respectively) to human CYP2B6.
CYP2B6 has been reported to be increased in the brain of smokers
in a pilot study (Miksys et al., 2003) and is thought to be involved in
PCB metabolism in humans (Ariyoshi et al., 1995; Warner et al.,
2008).
CYP1A2 mRNA was detected in cortex, hippocampus and
cerebellum across all eight experimental groups (Tables 1 and
2), whereas CYP2B3 and CYP3A2 transcripts were detected only
in cerebellum. Exposure to nicotine alone or in combination
with PCB 95 did not alter P450 mRNA expression proﬁles in
cortex or cerebellum (Tables 1 and 2). In the hippocampus,
treatment with nicotine alone for 3, but not 1 or 7 consecutive
days, downregulated CYP1A2 mRNA relative to vehicle
control (0.54-fold decrease, p = 0.013, 95% conﬁdenceinterval = 0.331–0.779; Table 1). Neither nicotine nor PCB 95,
alone or in combination, altered hippocampal expression of
CYP2B3 or CYP3A2 mRNA (Tables 1 and 2).
In the liver, CYP1A2, CYP2B3 and CYP3A2 mRNA was detected
across all experimental groups (Tables 1 and 2). CYP2B3 and
CYP1A2 mRNA were unchanged by exposure to nicotine or PCB 95,
alone or in combination. However, co-exposure to nicotine and P
CB 95 upregulated CYP3A2 transcripts relative to all other
experimental conditions (Table 2): 3.54-fold increase compared
to nicotine only (p = 0.008, 95% CI: 1.790–6.441); 2.38-fold increase
compared to vehicle control (p = 0.006, 95% CI: 1.187–4.911); and
1.87-fold increase compared to PCB 95 only (p = 0.04, 95% CI:
0.893–3.508). Exposure to PCB 95 alone did not change hepatic
CYP3A2 mRNA relative to vehicle control.
4. Discussion
The goal of this study was to determine whether nicotine
co-exposure modiﬁes the enantioselective disposition of a
neurotoxic PCB congener in the brain via changes in brain and/
or hepatic CYP2B levels. PCB 95 was detected in all tissues
investigated, including the brain (cortex and cerebellum). The
hydroxylated metabolites of PCB 95 were detected in the liver and
blood, but not the brain of animals exposed to PCB 95, which is in
agreement with previous ﬁndings in mice (Kania-Korwel et al.,
2012). Nicotine co-exposure did not change levels of either the PCB
95 parent compound or its metabolites in any tissue investigated.
We observed signiﬁcant enantiomeric enrichment of the E1-PCB
95 enantiomer in the cortex. While enantiomeric enrichment of
PCB 95 has also been observed in mice, in contrast to rat, E2-PCB 95
is enriched in the mouse brain (Kania-Korwel et al., 2012).
Co-exposure to nicotine had no signiﬁcant effect on the
enantiomeric enrichment of PCB 95 in the cortex or in peripheral
tissues. Because the structurally related 2,20,3,30,6,60-hexachlor-
obiphenyl (PCB 136) atropselectively affects neuronal connectivity
(Pessah et al., 2009; Yang et al., 2014), further studies are needed to
assess the toxicological relevance of the highly species-dependent
atropisomeric enrichment in rats versus mice.
The lack of effect of nicotine on the disposition of PCB 95 in the
adult male rat brain most likely is due to the fact that CYP2B
expression was not induced by nicotine treatment in any
experimental group in our study. While our ﬁnding is consistent
with a previous report that a 20 day exposure to tobacco smoke did
not upregulate CYP2B1/2 in adult female Wistar rats (Czekaj et al.,
2000), it is in contrast to previous studies of adult male Wistar rats
(Miksys et al., 2000; Khokhar et al., 2010). One potential
explanation for the discrepancy between our observations and
these latter studies is the dose of nicotine used. While one of these
latter studies (Miksys et al., 2000) did show increased CYP2B
expression in the brain following 7 d of repeated injections of
nicotine base at 300 mg/kg/d, these changes were primarily limited
to the brain stem and olfactory cortex with no change in CYP2B
mRNA in other brain regions and only modest (0.76-fold) increase
in CYP2B protein in the frontal cortex. Signiﬁcant increases in
CYP2B mRNA and proteins levels in the frontal cortex, hippocam-
pus and cerebellum were only observed in the brains of animals
repeatedly injected with nicotine base at 1.0 mg/kg/d, which is
approximately 3 times the dose we used (325 mg/kg/d, expressed
as the free base).
Another key difference between our observations and the
studies reported by the group that has demonstrated nicotine
induction of brain CYP2B1 is that we did not detect constitutive
expression of CYP2B1 mRNA in cortex, cerebellum and hippocam-
pus or CYP2B protein in the cortex of adult male Wistar rats. While
these ﬁndings agree with our previous observation that
CYP2B1 mRNA is not detected in the adult Sprague Dawley rat
Fig. 5. Effect of nicotine and/or PCB 95 exposure on liver and brain CYP2B protein levels. Total protein of microsomes isolated from the liver and the cortex of rats treated with
saline, nicotine, saline plus PCB 95, or nicotine plus PCB 95 (experimental groups (i)–(iv) as described in Section 2.2 and illustrated in Fig. 2) were separated by SDS gel
electrophoresis and probed with a polyclonal antibody against CYP2B. Representative blots demonstrating detection of CYP2B (arrow) in liver (LV) but not cortical (CX)
microsomes from (A) vehicle or nicotine-treated animals; (B) PCB 95-exposed animals; and (C) animals co-exposed to nicotine and PCB 95. GAPDH (arrowhead) was probed as
a loading control. (D) Densitometric analyses of liver CYP2B protein normalized to GAPDH as a percentage of vehicle controls. Data are presented as box plots in which the
horizontal line in each box represents the median, the boundary of the box represents the 25th–75th percentiles and the whiskers represent 1st–99th percentiles
(n = 4 animals per experimental group). The CYP2B1/GAPDH densitometric ratio was signiﬁcantly lower in the liver samples of animals co-exposed to PCB 95 and nicotine
compared to animals exposed to nicotine alone (one-way ANOVA with Tukey post hoc test; *p < 0.05). B, loading buffer control; PB, liver microsomes from an adult male rat
treated with phenobarbital; S, supersomes (recombinant rat CYP2B1).
Table 1
Nicotine does not cause widespread changes in P450 mRNA levels in the brain or
liver of adult male rats after 1 or 3 d of daily injections.a
Cortex Hippocampus Cerebellum Liver
1 d 3 d 1 d 3 d 1 d 3 d 1 d 3 d
CYP2B1       0.89 0.77
CYP2B3     0.63 0.81 0.74 0.79
CYP3A2     1.00 0.95 0.75 1.32
CYP1A2 1.92 0.42 0.96 #0.54b 0.97 0.91 0.93 1.50
, indicates mRNA was not detected.
a Adult male rats were injected with nicotine (1 mg/kg/d, s.c.) or an equal volume
(0.3 ml) of vehicle (sterile saline) for 1 or 3 d (experimental groups (v)–(viii) in
Fig. 2). The fold change in mRNA expression in tissues from nicotine-treated animals
relative to vehicle controls was calculated using the REST2009 software (Qiagen),
which incorporates Ct and efﬁciency values determined by qPCR analysis (Stamou
et al., 2014).
b # indicates signiﬁcant downregulation of gene expression (p < 0.05).
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phenobarbital or dexamethasone at levels that induced hepatic
P450 expression (Stamou et al., 2014), and they are consistent with
a previous study of CYP2B expression in the brain of adult female
Wistar rats (Czekaj et al., 2000), they are in contrast to studies that
reported constitutive expression of CYP2B1 in the male rat brain
(Miksys et al., 2000; Khokhar et al., 2010). Differences in the
animals’ environment, including housing, husbandry and diet, may
account for differences in the constitutive levels of CYP2B1 in the
brain between studies (Ronis et al., 1999; Kozul et al., 2008), which
in turn may determine the response to nicotine.
An alternate explanation is that nicotine and/or PCB 95 altered
the expression of P450 enzymes other than CYP2B1/2 and those
changes offset the effect of nicotine on CYP2B1-mediated PCB
95 metabolism and/or changed the metabolism of nicotine itself.
The latter possibility is suggested by evidence that PCBs can be
metabolized by multiple P450s (Hrycay and Bandiera, 2003;
Table 2
Fold-change in P450 mRNA levels in adult male rats exposed to vehicle (saline), 1 mg/kg nicotine (s.c. once daily, days 1–7) or 6 mg/kg PCB95 (p.o. in peanut butter once daily,
days 1–6) alone or in combination.a
Nicotine vs. vehicle PCB 95 vs. vehicle Nicotine + PCB 95 vs. vehicle Nicotine + PCB 95 vs. nicotine Nicotine + PCB 95 vs. PCB 95
Cortex
CYP2B1     
CYP2B3     
CYP3A2     
CYP1A2 6.74 0.95 2.16 0.32 2.28
Hippocampus
CYP2B1     
CYP2B3     
CYP3A2 1.64    
CYP1A2 0.49 0.18 0.19 0.38 1.11
Cerebellum
CYP2B1     
CYP2B3 0.57 0.29 0.32 0.49 1.10
CYP3A2 1.05 0.59 0.90 0.86 1.53
CYP1A2 1.15 1.98 2.11 1.84 1.06
Liver
CYP2B1 0.71 2.08 "2.81b 3.96 1.35
CYP2B3 0.79 0.90 0.95 1.20 1.05
CYP3A2 0.67 1.27 "2.38b "3.54b "1.87b
CYP1A2 0.80 1.31 1.62 2.02 1.23
, indicates mRNA was not detected.
a Corresponds to experimental groups (i)–(iv) in Fig. 2.
b Indicates statistically signiﬁcant change (": upregulation/ #: downregulation) of gene expression (p < 0.05). The relative expression (shown in bold) was calculated using
the REST2009 software (Qiagen), which incorporates Ct and efﬁciency values determined by qPCR analysis (Stamou et al., 2014).
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that both nicotine and PCB 95 can inﬂuence their own
toxicokinetics by regulating the levels of P450 enzymes that
metabolize them (Dannan et al., 1983; Miksys et al., 2000;
Twaroski et al., 2001; Gahrs et al., 2013). However, in the present
study, exposure to nicotine or PCB 95 alone or in combination did
not cause widespread changes in the transcriptional proﬁle of
CYP1A2, CYP2B3 or CYP3A2 in the brain regions examined, in
agreement with the lack of effect of classic P450 inducers on
region-selective P450 expression of these transcripts in the rat
brain (Stamou et al., 2014). The one exception to this generalization
was that exposure to nicotine for 3 d, but not 1 or 7 d,
downregulated hippocampal CYP1A2 expression. Evidence for
CY1A2 transcriptional regulation by nicotine in liver and/or brain
has been shown in rodents (Anandatheerthavarada et al., 1993b;
Price et al., 2004), although in humans, nicotine has been reported
to have no effect on CYP1A2 activity (Hukkanen et al., 2011).
CYP1A2 has been implicated in PCB metabolism (Fitzgerald et al.,
2005; Zhou et al., 2010; Curran et al., 2011); however, whether its
transient downregulation in the hippocampus is functionally
relevant to PCB neurotoxicity has yet to be determined.
Co-exposure to nicotine and PCB 95 signiﬁcantly increased
CYP3A2 and CYP2B1 mRNA in the liver. The increase in hepatic
CYP2B1 mRNA was accompanied by a signiﬁcant decrease in CYP2B
protein in the liver. Discrepancies between CYP expression at the
mRNA versus the protein level have been widely documented
[reviewed by Collins et al. (2012)], and in a recent study of
puromycin amino-nucleoside-induced cytotoxicity in glomerular
epithelial cells, increased CYP2B1 mRNA was observed as a
consequence of decreased CYP2B1 protein (Tian et al., 2010),
suggesting the possibility that transcript levels are upregulated as
a compensatory response to decreased protein levels. Collectively,
these data support previous studies suggesting that transcriptional
regulation of P450s in the brain is distinct from that in the liver
(Meyer et al., 2007; Stamou et al., 2014). Furthermore, these data
suggest that nicotine and PCB 95 interact to alter P450 expression
in the liver but not in the brain. However, these changes in hepaticCYP2B1 expression are likely transient (Lee et al., 2008) and,
therefore, not sufﬁcient to signiﬁcantly alter PCB 95 disposition at
the dose used in our study.
5. Conclusions
Our study is the ﬁrst to demonstrate that PCB 95 is
enantioselectively metabolized to potentially neurotoxic OH-PCBs
(Niknam et al., 2013) in the male rat, with a pronounced
enrichment of E1-PCB 95. However, in contrast to previous studies
indicating that nicotine alters the kinetics and dynamics of
neuroactive compounds metabolized by P450 enzymes, speciﬁ-
cally chlorpyrifos (Lee et al., 2008) and propofol (Khokhar and
Tyndale, 2011), nicotine did not signiﬁcantly alter the disposition
or enantiomeric enrichment of PCB 95 in the brain or peripheral
tissues of adult male rats in our study. This can be explained in
large part by our observations that CYP2B1/2 protein is not
expressed in the brain of male rats and nicotine treatment alone
does not signiﬁcantly alter the expression of CYP2B1/2 and other
P450 enzymes in the brain or liver. Although our data strongly
suggest that PCB 95 disposition is not affected by exposure to
nicotine, the P450 gene expression changes observed in animals
co-exposed to nicotine and PCB 95 indicate a previously unknown
mixture effect on hepatic gene expression. Considering the rapidly
increasing use of e-cigarettes, this observation warrants further
investigation.
Acknowledgments
This work was supported by the National Institutes of Health
National Institute of Environmental Health Sciences [Grants
R01 ES017425,P42 ES04699, P01 ES011269] and by the United
States Environmental Protection Agency [grant R833292]. Its
contents are solely the responsibility of the grantee and do not
necessarily represent the ofﬁcial views of the agency that provided
the grant. Furthermore the grant agencies do not endorse the
purchase of any commercial products or services mentioned in the
M. Stamou et al. / Toxicology 338 (2015) 59–68 67publication. We thank Jaya Bharati Muvvala (UC Davis) for her
technical assistance with qPCR, Dr. Stelvio Bandiera (University of
British Columbia) for generously providing the rabbit polyclonal
anti-CYP2B1/2 antibody, and Dr. Xueshu Li (The University of Iowa)
for recording the NMR spectra of the nicotine salt. We also thank
Dr. Kim Keil, Dr. Adrienne Bautista and Mr. Hao Chen (UC Davis) for
providing critical feedback on early drafts of the manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.tox.2015.10.002.
References
Anandatheerthavarada, H.K., Williams, J.F., Wecker, L., 1993a. The chronic
administration of nicotine induces cytochrome p450 in rat brain. J. Neurochem.
60, 1941–1944.
Anandatheerthavarada, H.K., Williams, J.F., Wecker, L., 1993b. Differential effect of
chronic nicotine administration on brain cytochrome p4501a1/2 and p4502e1.
Biochem. Biophys. Res. Commun. 194, 312–318. doi:http://dx.doi.org/10.1006/
bbrc.1993.1821.
Ariyoshi, N., Oguri, K., Koga, N., Yoshimura, H., Funae, Y., 1995. Metabolism of highly
persistent pcb congener, 2,4,5,2,4,5-hexachlorobiphenyl, by human cyp2b6.
Biochem. Biophys. Res. Commun. 212, 455–460. doi:http://dx.doi.org/10.1006/
bbrc.1995.1991.
Birnbaum, L.S., 1983. Distribution and excretion of 2,3,6,2',3',6'- and 2,4,5,2',4',5'-
hexachlorobiphenyl in senescent rats. Toxicol. Appl. Pharmacol. 70, 262–272.
Collins, B.C., Miller, C.A., Sposny, A., Hewitt, P., Wells, M., Gallagher, W.M.,
Pennington, S.R., 2012. Development of a pharmaceutical hepatotoxicity
biomarker panel using a discovery to targeted proteomics approach. Mol. Cell.
Proteomics 11, 394–410. doi:http://dx.doi.org/10.1074/mcp.M111.016493.
Crane, A.L., Klein, K., Zanger, U.M., Olson, J.R., 2012. Effect of cyp2b6*6 and
cyp2c19*2 genotype on chlorpyrifos metabolism. Toxicology 293, 115–122. doi:
http://dx.doi.org/10.1016/j.tox.2012.01.006.
Curran, C.P., Nebert, D.W., Genter, M.B., Patel, K.V., Schaefer, T.L., Skelton, M.R.,
Williams, M.T., Vorhees, C.V., 2011. In utero and lactational exposure to pcbs in
mice: adult offspring show altered learning and memory depending on
cyp1a2 and ahr genotypes. Environ. Health Perspect.119,1286–1293. doi:http://
dx.doi.org/10.1289/ehp.1002965.
Czekaj, P., Wiaderkiewicz, A., Florek, E., Wiaderkiewicz, R., 2000. Expression of
cytochrome cyp2b1/2 in nonpregnant, pregnant and fetal rats exposed to
tobacco smoke. Acta Biochim. Pol. 47, 1115–1127.
Dannan, G.A., Guengerich, F.P., Kaminsky, L.S., Aust, S.D., 1983. Regulation of
cytochrome p-450. Immunochemical quantitation of eight isozymes in liver
microsomes of rats treated with polybrominated biphenyl congeners. J. Biol.
Chem. 258, 1282–1288.
Dutheil, F., Jacob, A., Dauchy, S., Beaune, P., Scherrmann, J.M., Decleves, X., Loriot, M.
A., 2010. Abc transporters and cytochromes p450 in the human central nervous
system: inﬂuence on brain pharmacokinetics and contribution to
neurodegenerative disorders. Expert Opin. Drug Metab. Toxicol. 6, 1161–1174.
doi:http://dx.doi.org/10.1517/17425255.2010.510832.
Feo, M.L., Gross, M.S., McGarrigle, B.P., Eljarrat, E., Barceló, D., Aga, D.S., Olson, J.R.,
2012. Biotransformation of bde-47 to potentially toxic metabolites is
predominantly mediated by human cyp2b6. Environ. Health Perspect. 121, 440–
446.
Fitzgerald, E.F., Hwang, S.-A., Lambert, G., Gomez, M., Tarbell, A., 2005. Pcb exposure
and in vivo cyp1a2 activity among native americans. Environ. Health Perspect.
113, 272–277. doi:http://dx.doi.org/10.2307/3436039.
Foxenberg, R.J., Ellison, C.A., Knaak, J.B., Ma, C., Olson, J.R., 2011. Cytochrome p450-
speciﬁc human pbpk/pd models for the organophosphorus pesticides:
chlorpyrifos and parathion. Toxicology 285, 57–66. doi:http://dx.doi.org/
10.1016/j.tox.2011.04.002.
Gahrs, M., Roos, R., Andersson, P.L., Schrenk, D., 2013. Role of the nuclear xenobiotic
receptors car and pxr in induction of cytochromes p450 by non-dioxinlike
polychlorinated biphenyls in cultured rat hepatocytes. Toxicol. Appl. Pharmacol.
272, 77–85. doi:http://dx.doi.org/10.1016/j.taap.2013.05.034.
Hrycay, E.G., Bandiera, S.M., 2003. Spectral interactions of tetrachlorobiphenyls
with hepatic microsomal cytochrome p450 enzymes. Chem. Biol. Interact. 146,
285–296.
Hukkanen, J., Jacob 3rd, P., Peng, M., Dempsey, D., Benowitz, N.L., 2011. Effect of
nicotine on cytochrome p450 1a2 activity. Br. J. Clin. Pharmacol. 72, 836–838.
doi:http://dx.doi.org/10.1111/j.1365-2125.2011.04023.x.
Joshi, S.N., Vyas, S.M., Duffel, M.W., Parkin, S., Lehmler, H.J., 2011. Synthesis of
sterically hindered polychlorinated biphenyl derivatives. Synthesis 2011, 1045–
1054. doi:http://dx.doi.org/10.1055/s-0030-1258454.
Kania-Korwel, I., Barnhart, C.D., Stamou, M., Truong, K.M., El-Komy, M.H.M.E., Lein, P.
J., Veng-Pedersen, P., 2012. 2,20 ,3,50 ,6-pentachlorobiphenyl (pcb 95) and its
hydroxylated metabolites are enantiomerically enriched in female mice.
Environ. Sci. Technol. 46, 11393–11401. doi:http://dx.doi.org/10.1021/
es302810t.Kania-Korwel, I., Lehmler, H.J., 2015. Chiral polychlorinated biphenyls: absorption,
metabolism and excretion – a review. Environ. Sci. Pollut. Res. Int. doi:http://dx.
doi.org/10.1007/s11356-015-4150-2.
Kania-Korwel, I., Shaikh, N.S., Hornbuckle, K.C., Robertson, L.W., Lehmler, H.-J., 2007.
Enantioselective disposition of pcb 136 (2,2,3,3,6,6-hexachlorobiphenyl) in
c57bl/6 mice after oral and intraperitoneal administration. Chirality 19, 56–66.
doi:http://dx.doi.org/10.1002/chir.20342.
Kania-Korwel, I., Vyas, S.M., Song, Y., Lehmler, H.-J., 2008. Gas chromatographic
separation of methoxylated polychlorinated biphenyl atropisomers. J.
Chromatogr. A 1207, 146–154. doi:http://dx.doi.org/10.1016/j.
chroma.2008.08.044.
Khokhar, J.Y., Miksys, S.L., Tyndale, R.F., 2010. Rat brain cyp2b induction by nicotine
is persistent and does not involve nicotinic acetylcholine receptors. Brain Res.
1348, 1–9. doi:http://dx.doi.org/10.1016/j.brainres.2010.06.035.
Khokhar, J.Y., Tyndale, R.F., 2011. Drug metabolism within the brain changes drug
response: selective manipulation of brain cyp2b alters propofol effects.
Neuropsychopharmacology 36, 692–700. doi:http://dx.doi.org/10.1038/
npp.2010.202.
Kim, K.H., Bose, D.D., Ghogha, A., Riehl, J., Zhang, R., Barnhart, C.D., Lein, P.J., Pessah, I.
N., 2011. Para- and ortho-substitutions are key determinants of polybrominated
diphenyl ether activity toward ryanodine receptors and neurotoxicity. Environ.
Health Perspect. 119, 519–526. doi:http://dx.doi.org/10.1289/ehp.1002728.
Kozul, C.D., Nomikos, A.P., Hampton, T.H., Warnke, L.A., Gosse, J.A., Davey, J.C.,
Thorpe, J.E., Jackson, B.P., Ihnat, M.A., Hamilton, J.W., 2008. Laboratory diet
profoundly alters gene expression and confounds genomic analysis in mouse
liver and lung. Chem. Biol. Interact. 173, 129–140. doi:http://dx.doi.org/10.1016/
j.cbi.2008.02.008.
Le Houezec, J., Jacob 3rd, P., Benowitz, N.L., 1993. A clinical pharmacological study of
subcutaneous nicotine. Eur. J. Clin. Pharmacol. 44, 225–230.
Lee, S., Busby, A.L., Timchalk, C., Poet, T.S., 2008. Effects of nicotine exposure on in
vitro metabolism of chlorpyrifos in male sprague-dawley rats. J. Toxicol.
Environ. Health Part A 72, 74–82. doi:http://dx.doi.org/10.1080/
15287390802477288.
Lehmler, H.-J., Harrad, S.J., Huhnerfuss, H., Kania-Korwel, I., Lee, C.M., Lu, Z., Wong, C.
S., 2010. Chiral polychlorinated biphenyl transport, metabolism, and
distribution: a review. Environ. Sci. Technol. 44, 2757–2766. doi:http://dx.doi.
org/10.1021/es902208u.
Lu, Z., Kania-Korwel, I., Lehmler, H.J., Wong, C.S., 2013. Stereoselective formation of
mono- and dihydroxylated polychlorinated biphenyls by rat cytochrome p450
2b1. Environ. Sci. Technol. 47, 12184–12192. doi:http://dx.doi.org/10.1021/
es402838f.
Matta, S.G., Balfour, D.J., Benowitz, N.L., Boyd, R.T., Buccafusco, J.J., Caggiula, A.R.,
Craig, C.R., Collins, A.C., Damaj, M.I., Donny, E.C., Gardiner, P.S., Grady, S.R.,
Heberlein, U., Leonard, S.S., Levin, E.D., Lukas, R.J., Markou, A., Marks, M.J.,
McCallum, S.E., Parameswaran, N., Perkins, K.A., Picciotto, M.R., Quik, M., Rose, J.
E., Rothenﬂuh, A., Schafer, W.R., Stolerman, I.P., Tyndale, R.F., Wehner, J.M.,
Zirger, J.M., 2007. Guidelines on nicotine dose selection for in vivo research.
Psychopharmacology (Berl) 190, 269–319.
Meyer, R.P., Gehlhaus, M., Knoth, R., Volk, B., 2007. Expression and function of
cytochrome p450 in brain drug metabolism. Curr. Drug Metab. 8, 297–306.
Miksys, S., Hoffmann, E., Tyndale, R.F., 2000. Regional and cellular induction of
nicotine-metabolizing cyp2b1 in rat brain by chronic nicotine treatment.
Biochem. Pharmacol. 59, 1501–1511. doi:http://dx.doi.org/10.1016/s0006-2952
(00) 00281-1.
Miksys, S., Lerman, C., Shields, P.G., Mash, D.C., Tyndale, R.F., 2003. Smoking,
alcoholism and genetic polymorphisms alter cyp2b6 levels in human brain.
Neuropharmacology 45, 122–132.
Miksys, S., Tyndale, R.F., 2013. ccnp heinz lehmann award paper: cytochrome p450-
mediated drug metabolism in the brain. J. Psychiatry Neurosci. 38,152–163. doi:
http://dx.doi.org/10.1503/jpn.120133.
Niknam, Y., Feng, W., Cherednichenko, G., Dong, Y., Joshi, S.N., Vyas, S.M., Lehmler,
H.-J., Pessah, I.N., 2013. Structure-activity relationship of select meta- and para-
hydroxylated non-dioxin-like polychlorinated biphenyls: from single
ryr1 channels to muscle dysfunction. Toxicol. Sci. 136, 500–513.
Noel, J.K., Rees, V.W., Connolly, G.N., 2011. Electronic cigarettes: a new ‘tobacco’
industry? Tob. Control 20, 81. doi:http://dx.doi.org/10.1136/tc.2010.038562.
Panesar, S.K., Bandiera, S.M., Abbott, F.S., 1996. Comparative effects of
carbamazepine and carbamazepine-10,11-epoxide on hepatic cytochromes
p450 in the rat. Drug Metab. Dispos. 24, 619–627.
Pessah, I.N., Cherednichenko, G., Lein, P.J., 2010. Minding the calcium store:
ryanodine receptor activation as a convergent mechanism of pcb toxicity.
Pharmacol. Ther. 125, 260–285. doi:http://dx.doi.org/10.1016/j.
pharmthera.2009.10.009.
Pessah, I.N., Lehmler, H.-J., Robertson, L.W., Perez, C.F., Cabrales, E., Bose, D.D., Feng,
W., 2009. Enantiomeric speciﬁcity of ()-2,2',3,3',6,6'-hexachlorobiphenyl
toward ryanodine receptor types 1 and 2. Chem. Res. Toxicol. 22, 201–207.
Pfafﬂ, M.W., 2001. A new mathematical model for relative quantiﬁcation in real-
time rt–pcr. Nucleic Acids Res. 29, e45. doi:http://dx.doi.org/10.1093/nar/29.9.
e45.
Price, R.J., Renwick, A.B., Walters, D.G., Young, P.J., Lake, B.G., 2004. Metabolism of
nicotine and induction of cyp1a forms in precision-cut rat liver and lung slices.
Toxicol. In Vitro 18, 179–185.
Regan, A.K., Promoff, G., Dube, S.R., Arrazola, R., 2013. Electronic nicotine delivery
systems: adult use and awareness of the ‘e-cigarette' in the USA. Tob. Control 22,
19–23. doi:http://dx.doi.org/10.1136/tobaccocontrol-2011-050044.
68 M. Stamou et al. / Toxicology 338 (2015) 59–68Ronis, M.J., Rowlands, J.C., Hakkak, R., Badger, T.M., 1999. Altered expression and
glucocorticoid-inducibility of hepatic cyp3a and cyp2b enzymes in male rats fed
diets containing soy protein isolate. J. Nutr. 129, 1958–1965.
Siemens, N., Patenge, N., Otto, J., Fiedler, T., Kreikemeyer, B., 2011. Streptococcus
pyogenes m49 plasminogen/plasmin binding facilitates keratinocyte invasion
via integrin-integrin-linked kinase (ilk) pathways and protects from
macrophage killing. J. Biol. Chem. 286, 21612–21622. doi:http://dx.doi.org/
10.1074/jbc.M110.202671.
Stamou, M., Wu, X., Kania-Korwel, I., Lehmler, H.J., Lein, P.J., 2014. Cytochrome p450
mrna expression in the rodent brain: species-, sex-, and region-dependent
differences. Drug Metab. Dispos. 42, 239–244. doi:http://dx.doi.org/10.1124/
dmd.113.054239.
Tian, N., Arany, I., Waxman, D.J., Baliga, R., 2010. Cytochrome-p450 2b1 gene
silencing attenuates puromycin aminonucleoside-induced cytotoxicity in
glomerular epithelial cells. Kidney Int. 78, 182–190. doi:http://dx.doi.org/
10.1038/ki.2010.100.
Twaroski, T.P., O’Brien, M.L., Larmonier, N., Glauert, H.P., Robertson, L.W., 2001.
Polychlorinated biphenyl-induced effects on metabolic enzymes, ap-1 binding,
vitamin e, and oxidative stress in the rat liver. Toxicol. Appl. Pharmacol. 171, 85–
93. doi:http://dx.doi.org/10.1006/taap.2000.9114.
Warner, N.A., Martin, J.W., Wong, C.S., 2008. Chiral polychlorinated biphenyls are
biotransformed enantioselectively by mammalian cytochrome p-450 isozymes
to form hydroxylated metabolites. Environ. Sci. Technol. 43, 114–121. doi:http://
dx.doi.org/10.1021/es802237u.Wu, X., Kania-Korwel, I., Chen, H., Stamou, M., Dammanahalli, K.J., Duffel, M., Lein, P.
J., Lehmler, H.J., 2013. Metabolism of 2,2',3,3',6,6'-hexachlorobiphenyl (pcb 136)
atropisomers in tissue slices from phenobarbital or dexamethasone-induced
rats is sex-dependent. Xenobiotica 43, 933–947. doi:http://dx.doi.org/10.3109/
00498254.2013.785626.
Wu, X., Pramanik, A., Duffel, M.W., Hrycay, E.G., Bandiera, S.M., Lehmler, H.J.,
Kania-Korwel, I., 2011. 2,2',3,3',6,6'-hexachlorobiphenyl (pcb 136) is
enantioselectively oxidized to hydroxylated metabolites by rat liver
microsomes. Chem. Res. Toxicol. 24, 2249–2257. doi:http://dx.doi.org/
10.1021/tx200360m.
Yamin, C.K., Bitton, A., Bates, D.W., 2010. E-cigarettes: a rapidly growing internet
phenomenon. Ann. Intern. Med. 153, 607–609. doi:http://dx.doi.org/10.7326/
0003-4819-153-9-201011020-00011.
Yang, D., Kania-Korwel, I., Ghogha, A., Chen, H., Stamou, M., Bose, D.D., Pessah, I.N.,
Lehmler, H.J., Lein, P.J., 2014. Pcb 136 atropselectively alters morphometric and
functional parameters of neuronal connectivity in cultured rat hippocampal
neurons via ryanodine receptor-dependent mechanisms. Toxicol. Sci. 138, 379–
392. doi:http://dx.doi.org/10.1093/toxsci/kft334.
Zhou, S.F., Wang, B., Yang, L.P., Liu, J.P., 2010. Structure, function, regulation and
polymorphism and the clinical signiﬁcance of human cytochrome p450 1a2.
Drug Metab. Rev. 42, 268–354. doi:http://dx.doi.org/10.3109/
03602530903286476.
